{"product_id":"your-genes-and-heart-disease-how-modern-genetics-is-revolutionizing-coronary-artery-disease-care","title":"Your Genes and Heart Disease: How Modern Genetics Is Revolutionizing Coronary Artery Disease Care","description":"\u003cp\u003eHeart disease remains the world's leading cause of death, and for decades doctors have known that it often runs in families. This article explains how modern genetic research—particularly genome-wide association studies (GWAS)—has transformed our understanding of why some people develop coronary artery disease (CAD) while others do not, and how this knowledge is already leading to new treatments and, potentially, personalized prevention strategies. The original review, published in \u003cem\u003eJACC: Basic to Translational Science\u003c\/em\u003e in 2021, summarizes more than a decade of genetic discoveries that have identified over 200 genetic regions linked to heart disease risk and are now reshaping how we think about prevention, diagnosis, and treatment.\u003c\/p\u003e\n\n\u003ch1\u003eYour Genes and Heart Disease: How Modern Genetics Is Revolutionizing Coronary Artery Disease Care\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#introduction\"\u003eIntroduction: Why Family History Matters\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#methods\"\u003eStudy Methods: How Researchers Hunt for Heart Disease Genes\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#key-findings\"\u003eKey Findings: A New Genetic Landscape for Heart Disease\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#challenges\"\u003eThe Challenge: From Gene Discovery to Understanding Disease\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#lipid-metabolism\"\u003eNew Insights into Cholesterol and Triglycerides\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#vascular-wall\"\u003eGenes That Affect the Blood Vessel Wall\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#polygenic-scores\"\u003ePolygenic Risk Scores: Personalized Medicine in Action\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#clinical-implications\"\u003eWhat This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eStudy Limitations\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eFamily history of early heart attack or coronary artery disease increases risk, especially before age 55 in men or 65 in women.\u003c\/li\u003e\n\u003cli\u003eOver 200 genetic regions linked to coronary artery disease have been identified, but each has a small effect.\u003c\/li\u003e\n\u003cli\u003ePolygenic risk scores can predict heart disease risk from birth, but accuracy varies by ancestry.\u003c\/li\u003e\n\u003cli\u003eGenetic discoveries led to new lipid-lowering drugs including PCSK9 inhibitors, ezetimibe, and ANGPTL3-targeted therapies.\u003c\/li\u003e\n\u003cli\u003eGenetic risk is not destiny; lifestyle changes and medication can offset risk, as genes interact with traditional risk factors.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"introduction\"\u003eIntroduction: Why Family History Matters\u003c\/h2\u003e\n\u003cp\u003eCardiovascular diseases are the leading killers worldwide. Among them, coronary atherosclerosis—the buildup of fatty plaque in the arteries that supply the heart—and its complications, including chronic or acute coronary syndromes and ischemic heart failure, are the most common. For many years, doctors have recognized that having a close family member with heart disease puts you at higher risk. But exactly \u003cem\u003ewhich\u003c\/em\u003e genes are involved remained a mystery.\u003c\/p\u003e\n\u003cp\u003eFifteen years ago, only two genetic causes of CAD were known: mutations in the low-density lipoprotein receptor (\u003cstrong\u003eLDLR\u003c\/strong\u003e) gene and mutations in the \u003cstrong\u003ePCSK9\u003c\/strong\u003e gene, both of which lead to familial hypercholesterolemia, a condition of dangerously high cholesterol. Today, thanks to advances in biotechnology, the picture is vastly different. Researchers now know that CAD results from an interplay of \u003cstrong\u003ehundreds of genetic risk variants\u003c\/strong\u003e that exist throughout the entire population. In a systems biology sense, these genes lay the cellular foundation upon which traditional risk factors—high blood pressure, diabetes, smoking, obesity, and even noise and air pollution—build and aggravate the disease.\u003c\/p\u003e\n\u003cp\u003eThis new understanding opens up exciting possibilities. By identifying the specific biological processes these genes control, researchers hope to develop novel treatments and, eventually, personalized prevention strategies tailored to each person's genetic makeup—the cornerstone of what is called \u003cstrong\u003eprecision medicine\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch2 id=\"methods\"\u003eStudy Methods: How Researchers Hunt for Heart Disease Genes\u003c\/h2\u003e\n\u003cp\u003eThe story of modern CAD genetics began with a landmark observation in 1994. Researchers Marenberg and colleagues reported that identical twins (monozygotic) and fraternal twins (dizygotic) had a significantly higher risk of dying from CAD if their twin had died from the disease at a young age. Similarly, people whose relatives had a myocardial infarction (\u003cstrong\u003eMI\u003c\/strong\u003e, or heart attack) faced elevated risk. These findings confirmed that genes play a powerful role.\u003c\/p\u003e\n\u003cp\u003eEarly attempts to identify the specific genes responsible were largely unsuccessful. Candidate gene studies—which focused on genes involved in traditional risk factors like the angiotensin-converting enzyme (ACE)—turned out to be \"dead-end streets.\" For a long time, only mutations in \u003cstrong\u003eLDLR\u003c\/strong\u003e and \u003cstrong\u003ePCSK9\u003c\/strong\u003e were considered causal, acting through the intermediate phenotype of high cholesterol.\u003c\/p\u003e\n\u003cp\u003eEverything changed in 2007, driven by two key developments:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNew genotyping technology:\u003c\/strong\u003e Researchers introduced arrays that enabled genome-wide genotyping of an increasing number of genetic variants, followed by sophisticated computational \"imputation\" of millions of additional variants that weren't directly measured.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eGlobal collaboration:\u003c\/strong\u003e Large international consortia formed to jointly investigate the genetics of CAD, pooling data from tens of thousands of patients.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003eThese efforts produced deep insights into the disease's genetic architecture. Major studies included the \u003cstrong\u003eUK Biobank\u003c\/strong\u003e, the \u003cstrong\u003eCARDIoGRAMplusC4D 1M+ Hearts project\u003c\/strong\u003e, and the \u003cstrong\u003eMillion Veteran Program\u003c\/strong\u003e, all primarily focused on people of European ancestry. However, genome-wide association studies (GWASs) have also been conducted in other ethnic groups, including Han Chinese and Japanese populations. Notably, a recently published large-scale GWAS in Japanese individuals revealed \u003cstrong\u003e43 novel genetic loci\u003c\/strong\u003e associated with CAD, highlighting the ongoing search for population-specific and trans-ancestry risk factors.\u003c\/p\u003e\n\u003cp\u003eThis diversity matters clinically: the accuracy of polygenic risk scores (discussed later) depends heavily on how well effect sizes of risk alleles are predicted across different genetic backgrounds.\u003c\/p\u003e\n\u003cp\u003eThe statistical bar for declaring a genetic variant \"associated\" with disease is extremely high. Researchers require a \u003cstrong\u003egenome-wide level of significance (p \u0026lt; 10⁻⁸)\u003c\/strong\u003e—meaning there is less than a one in 100 million chance the finding is due to random luck. Even so, each individual variant typically has a small effect on risk; it is the combination of many variants that matters.\u003c\/p\u003e\n\n\u003ch2 id=\"key-findings\"\u003eKey Findings: A New Genetic Landscape for Heart Disease\u003c\/h2\u003e\n\u003cp\u003eSince 2007, more than \u003cstrong\u003e200 genetic loci\u003c\/strong\u003e (specific locations on chromosomes) have been reported to be associated with CAD and MI. Each has its own risk allele, allele frequency, and candidate gene. Early on, only a handful of these loci could be explained by effects on classical risk factors such as hypertension or high cholesterol. Today, approximately \u003cstrong\u003eone-half of the loci\u003c\/strong\u003e can be attributed to specific pathophysiological pathways—many of them newly discovered \"drivers\" of heart disease.\u003c\/p\u003e\n\n\u003ch3\u003eThe Famous 9p21 Locus: A Genetic Mystery Solved\u003c\/h3\u003e\n\u003cp\u003eThe first major discovery in modern CAD genetics was the \u003cstrong\u003echromosome 9p21 locus\u003c\/strong\u003e, uncovered independently by three research consortia at the same time. Together with the \u003cstrong\u003eLPA locus\u003c\/strong\u003e (which encodes lipoprotein(a), a prothrombotic and proinflammatory particle), 9p21 represents the locus with the strongest effect on CAD risk. Scientists initially called 9p21 a \"gene desert\" because there was no obvious traditional candidate gene nearby. The closest genes encode cyclin-dependent kinase inhibitors 2A\/2B (\u003cstrong\u003eCDKN2A\/CDKN2B\u003c\/strong\u003e), which have been thoroughly investigated but not proven to be involved.\u003c\/p\u003e\n\u003cp\u003eThe real culprit may be a long noncoding RNA (\u003cstrong\u003elncRNA\u003c\/strong\u003e) called \u003cstrong\u003eANRIL\u003c\/strong\u003e. The risk allele at 9p21 is associated with increased expression of linear ANRIL, which in turn is linked to enhanced atherosclerosis. In contrast, \u003cstrong\u003ecircular ANRIL\u003c\/strong\u003e appears to be protective. A recent elegant study used genetic engineering in induced pluripotent stem cells (adult cells reprogrammed to an embryonic-like state) and showed that replacing the non-risk genotype with the risk genotype led to overexpression of ANRIL and pro-atherogenic changes in vascular smooth muscle cells—the cells that line and support blood vessel walls.\u003c\/p\u003e\n\n\u003ch3\u003eA Broader Picture Beyond Traditional Risk Factors\u003c\/h3\u003e\n\u003cp\u003eOne striking finding is that many CAD genes are \u003cstrong\u003enot\u003c\/strong\u003e involved in traditional risk factors like cholesterol or blood pressure. For example, the \u003cstrong\u003enitric oxide signaling pathway\u003c\/strong\u003e—well known for modulating vascular tone (the relaxation and constriction of blood vessels)—also plays a major role in precipitating genetic CAD risk. This opens entirely new vistas on the biological processes underlying heart disease.\u003c\/p\u003e\n\n\u003ch2 id=\"challenges\"\u003eThe Challenge: From Gene Discovery to Understanding Disease\u003c\/h2\u003e\n\u003cp\u003eFinding a genetic variant is only the first step. Figuring out what it actually \u003cem\u003edoes\u003c\/em\u003e is far harder. Researchers traditionally used the \"closest gene approach,\" reporting the gene located nearest to the detected variant as the likely culprit. But this strategy can be misleading.\u003c\/p\u003e\n\u003cp\u003eBioinformatics tools have helped. The \u003cstrong\u003eGTEx database\u003c\/strong\u003e, for example, includes genome-wide genotyping and transcriptome (gene expression) data from many human tissues. This allows researchers to identify \u003cstrong\u003eexpression quantitative trait loci\u003c\/strong\u003e—places in the genome where a variant is associated with differential expression of a gene that may be located far away. In such cases, the closest gene might not be the causal one at all.\u003c\/p\u003e\n\n\u003ch3\u003eA Surprising Twist at the 6p24 Locus\u003c\/h3\u003e\n\u003cp\u003eA prominent example is the \u003cstrong\u003echromosome 6p24 locus\u003c\/strong\u003e, which harbors the \u003cstrong\u003ePHACTR1\u003c\/strong\u003e gene. PHACTR1 was not only associated with CAD but also with spontaneous coronary artery dissection (a tearing of the artery wall) and coronary artery calcification. Experimental data seemed to support a role for PHACTR1 in calcification.\u003c\/p\u003e\n\u003cp\u003eHowever, an elegant experiment using \u003cstrong\u003eCRISPR-based genome editing\u003c\/strong\u003e in stem-cell-derived endothelial cells (cells lining the blood vessels) revealed a surprising result. Altering the risk variant at the 6p24 locus led to expression changes in \u003cstrong\u003eEDN1\u003c\/strong\u003e—the gene that encodes endothelin-1, a well-studied vasoconstrictor and modulator of vascular smooth muscle function—rather than PHACTR1. This finding was validated by showing that the variant was also associated with endothelin-1 precursor protein levels in plasma. In other words, the \"obvious\" gene wasn't the one doing the work.\u003c\/p\u003e\n\n\u003ch3\u003eLessons from Mouse Models\u003c\/h3\u003e\n\u003cp\u003eAnother strategy is to study \u003cstrong\u003etransgenic mouse models\u003c\/strong\u003e (mice genetically engineered to lack or overexpress specific genes) to examine atherosclerotic plaque formation. A recent review found that most CAD genes studied in atherosclerosis-prone mouse models produced consistent results. But there are caveats—mice and humans differ in important ways, and completely deleting a gene (\"knockout\") may be too artificial.\u003c\/p\u003e\n\u003cp\u003eConsider the \u003cstrong\u003eGUCY1A1\u003c\/strong\u003e locus (which encodes a receptor for nitric oxide). Humans with rare loss-of-function mutations in this gene, or with common noncoding variants, have increased CAD risk. Yet when researchers knocked out the mouse counterpart \u003cem\u003eGucy1a1\u003c\/em\u003e, the mice developed \u003cem\u003eenhanced\u003c\/em\u003e atherosclerotic plaque formation—the opposite of what the human genetic associations predicted. However, in a population-based approach in mice, a variant that reduced Gucy1a1 expression was indeed linked to enhanced plaque formation. This was done using the \u003cstrong\u003eHybrid Mouse Diversity Panel\u003c\/strong\u003e, a tool that leverages natural genetic variation in mice rather than artificial gene deletion. The discrepancy illustrates how subtle—and sometimes contradictory—the path from genotype to phenotype can be.\u003c\/p\u003e\n\n\u003ch2 id=\"lipid-metabolism\"\u003eNew Insights into Cholesterol and Triglycerides\u003c\/h2\u003e\n\u003cp\u003eWhile many CAD genes are novel, GWASs have also deepened our understanding of traditional risk pathways—especially lipid metabolism. The genes \u003cstrong\u003ePCSK9\u003c\/strong\u003e and \u003cstrong\u003eLDLR\u003c\/strong\u003e were early examples. But several others have expanded our view and may represent future treatment targets. Here are three promising examples, along with a summary of drug targets that have already emerged.\u003c\/p\u003e\n\n\u003ch3\u003eSORT1: A Complex Target with a Double-Edged Sword\u003c\/h3\u003e\n\u003cp\u003eThe chromosome 1p13.3 locus was identified early in the GWAS era. Experimental studies pointed to \u003cstrong\u003esortilin 1 (SORT1)\u003c\/strong\u003e, a protein that regulates plasma LDL cholesterol by interacting with APOB in the Golgi apparatus of liver cells (hepatocytes). The risk variant lowers SORT1 mRNA levels. But targeting SORT1 therapeutically is complicated: the enzyme affects a wide variety of biological processes, including proper function of neurotrophins (proteins that support neuron survival) and neuron viability. SORT1 has also been linked to frontotemporal dementia. Clinical trials using a monoclonal antibody against SORT1 for this neurological condition are already underway—including the \u003cstrong\u003eINFRONT-2\u003c\/strong\u003e trial (NCT03987295) and the \u003cstrong\u003eINFRONT-3\u003c\/strong\u003e trial (NCT04374136).\u003c\/p\u003e\n\n\u003ch3\u003eLipoprotein Lipase and Its Modulators: A Rich Source of Drug Targets\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003eLipoprotein lipase (LPL)\u003c\/strong\u003e is a vascular enzyme critically involved in metabolizing triglyceride-rich lipoproteins. The LPL locus harbors both common noncoding variants and rare variants that cause loss of function (increasing CAD risk) or gain of function (reducing risk). Importantly, not only LPL itself but also its endogenous regulators are associated with CAD, including \u003cstrong\u003eAPOA5\u003c\/strong\u003e, \u003cstrong\u003eAPOC3\u003c\/strong\u003e, \u003cstrong\u003eANGPTL4\u003c\/strong\u003e, and \u003cstrong\u003eANGPTL3\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eTreatment approaches are being investigated for most of these. \u003cstrong\u003eANGPTL3\u003c\/strong\u003e has shown particularly promising results: evinacumab, an anti-ANGPTL3 antibody, reduces plasma triglyceride levels and atherosclerotic plaque formation in mice. In humans, it has confirmed effects on triglycerides and, recently, a beneficial effect on LDL cholesterol as well.\u003c\/p\u003e\n\n\u003ch3\u003eTRIB1: A Less Mature Candidate\u003c\/h3\u003e\n\u003cp\u003eThe \u003cstrong\u003eTRIB1\u003c\/strong\u003e locus also influences lipid metabolism. There is an inverse correlation between TRIB1 expression in the liver and the expression of lipogenic (fat-producing) genes. In line with this, targeted overexpression of \u003cem\u003eTrib1\u003c\/em\u003e in wild-type mice reduced cholesterol levels. Whether this can be translated to human treatment remains to be seen, but it is a fascinating avenue.\u003c\/p\u003e\n\n\u003ch3\u003eTable 1: CAD Genes Already Used as Therapeutic Targets\u003c\/h3\u003e\n\u003cp\u003eThe following genes, identified through GWASs and linked to both CAD and lipid phenotypes, are already being used as therapeutic targets:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAPOC3\u003c\/strong\u003e (apolipoprotein C-III): The antisense inhibitor \u003cstrong\u003evolanesorsen\u003c\/strong\u003e produces a dose-dependent \u003cstrong\u003e31% to 71% reduction in triglycerides\u003c\/strong\u003e and is effective in familial chylomicronemia syndrome, a severe form of high triglycerides.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eANGPTL3\/4\u003c\/strong\u003e (angiopoietin-like proteins 3\/4): \u003cstrong\u003eEvinacumab\u003c\/strong\u003e, a monoclonal antibody against ANGPTL3, reduced plasma LDL cholesterol levels by \u003cstrong\u003e47%\u003c\/strong\u003e in patients with familial hypercholesterolemia.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003ePCSK9\u003c\/strong\u003e (proprotein convertase subtilisin\/kexin type 9): Monoclonal antibodies and antisense molecules that reduce PCSK9 function have been shown to lower LDL cholesterol and cardiovascular events.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLPA\u003c\/strong\u003e (lipoprotein(a)): Lipoprotein(a) can be reduced by lipid apheresis (a filtering procedure); the antisense drug \u003cstrong\u003eTQJ230\u003c\/strong\u003e is currently being investigated in a large clinical outcome trial called \u003cstrong\u003eLp(a)HORIZON\u003c\/strong\u003e (NCT04023552).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNPC1L1\u003c\/strong\u003e (Niemann-Pick C1-Like 1): \u003cstrong\u003eEzetimibe\u003c\/strong\u003e, an NPC1L1 inhibitor, reduced LDL cholesterol and cardiovascular events when added to statin therapy.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHMGCR\u003c\/strong\u003e (3-hydroxy-3-methylglutaryl-coenzyme A reductase): \u003cstrong\u003eStatins\u003c\/strong\u003e target this pivotal enzyme in cholesterol biosynthesis and have been repeatedly shown to reduce cardiovascular events.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"vascular-wall\"\u003eGenes That Affect the Blood Vessel Wall\u003c\/h2\u003e\n\u003cp\u003eBeyond lipid metabolism, a large number of risk genes influence processes in the \u003cstrong\u003evascular wall\u003c\/strong\u003e—the layers of cells that make up blood vessels. With growing knowledge about the involvement of immune cells and platelets in atherosclerosis, researchers are investigating the \"vascular interface\" where resident and circulating cells interact with lipids to form atherosclerotic plaques.\u003c\/p\u003e\n\n\u003ch3\u003eVascular Smooth Muscle Cells: The Unsung Heroes\u003c\/h3\u003e\n\u003cp\u003eVascular smooth muscle cells influence atherosclerosis through at least two mechanisms: first, by controlling vascular tone (and thus blood pressure), and second, through local processes like inflammation and vascular remodeling that can either stabilize or destabilize plaques. There is significant genetic overlap between these two functions.\u003c\/p\u003e\n\u003cp\u003eThe nitric oxide signaling pathway is a prime example. When nitric oxide is released, vascular smooth muscle cells produce the second messenger \u003cstrong\u003ecyclic guanosine monophosphate (cGMP)\u003c\/strong\u003e, leading to relaxation. Mice lacking the nitric oxide receptor in these cells develop hypertension. However, increased intracellular cGMP also inhibits migration of vascular smooth muscle cells—and cell migration is itself a hallmark of atherosclerosis progression. So the same pathway can have protective and harmful effects depending on the context.\u003c\/p\u003e\n\u003cp\u003eThe 9p21 locus also appears to exert its effects through vascular smooth muscle cell biology via ANRIL, as discussed earlier.\u003c\/p\u003e\n\n\u003ch3\u003eTCF21: A Master Regulator of Plaque Stability\u003c\/h3\u003e\n\u003cp\u003eA recent comprehensive study examined the role of the CAD gene \u003cstrong\u003eTCF21\u003c\/strong\u003e in atherosclerosis. A disease-associated variant in the 3' untranslated region of TCF21 alters its mRNA stability through differential binding of a \u003cstrong\u003emicroRNA\u003c\/strong\u003e—a fascinating example of gene regulation by noncoding RNAs. Researchers found that loss of \u003cem\u003eTcf21\u003c\/em\u003e inhibits the \"phenotype switch\" of vascular smooth muscle cells, resulting in fewer fibromyocytes in the fibrous cap of atherosclerotic plaques, which reduces plaque stability. The molecular mechanism involves an interaction between TCF21 and the myocardin-serum response factor pathway. Increasing TCF21 availability might help prevent plaques and stabilize existing ones, though more research is needed. Therapeutic targeting of the mRNA-microRNA interaction is complicated by the challenge of delivering such substances to vascular smooth muscle cells.\u003c\/p\u003e\n\n\u003ch3\u003eADAMTS7 and SVEP1: A Protease and Its Substrate\u003c\/h3\u003e\n\u003cp\u003eA more convenient target may be \u003cstrong\u003eADAMTS7\u003c\/strong\u003e, an extracellular matrix protease produced by endothelial cells and vascular smooth muscle cells. It degrades multiple members of the thrombospondin protein family. Mice lacking \u003cem\u003eAdamts-7\u003c\/em\u003e develop less atherosclerosis and are resistant to neointima formation (a type of vessel re-narrowing) after vascular injury. The downstream mechanisms aren't fully understood, but in the lab, ADAMTS-7 degrades \u003cstrong\u003eSVEP1\u003c\/strong\u003e (sushi, von Willebrand factor type A, EGF, and pentraxin domain containing 1), another extracellular matrix protein important in development and lymphatic vessel formation.\u003c\/p\u003e\n\u003cp\u003eSVEP1 itself was identified as a CAD gene through an exome-wide association study. Initial results suggest an atheroprotective role: \u003cem\u003eSvep1\u003c\/em\u003e haploinsufficiency (having only one working copy of the gene) promotes atherosclerotic plaque formation and recruitment of leukocytes (white blood cells) to the vessel wall. While questions remain about SVEP1's role as a circulating biomarker, the findings highlight the potential of \u003cstrong\u003eADAMTS7 inhibitors\u003c\/strong\u003e as an upstream therapeutic strategy.\u003c\/p\u003e\n\n\u003ch3\u003eHHIPL1: The Hedgehog Signaling Connection\u003c\/h3\u003e\n\u003cp\u003e\u003cstrong\u003eHHIPL1\u003c\/strong\u003e (hedgehog interacting protein-like 1) is a novel player in the vascular wall. It interacts with hedgehog signaling, a pathway indispensable for embryonic development—especially for the coronary vasculature—and for ischemia-driven neoangiogenesis (growth of new blood vessels). In atherosclerosis, HHIPL1 positively influences vascular smooth muscle cell migration and proliferation. Mice lacking \u003cem\u003eHhipl1\u003c\/em\u003e develop smaller atherosclerotic plaques, while blocking hedgehog signaling produces larger plaques. Notably, a recent analysis found considerable overlap between genetic variants that influence vascular smooth muscle cell phenotypes in vitro and variants associated with CAD in humans, reinforcing the importance of this cell type.\u003c\/p\u003e\n\n\u003ch2 id=\"polygenic-scores\"\u003ePolygenic Risk Scores: Personalized Medicine in Action\u003c\/h2\u003e\n\u003cp\u003eOne of the most exciting practical applications of CAD genetics is the \u003cstrong\u003epolygenic risk score (PRS)\u003c\/strong\u003e. The concept follows three steps:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eIdentification:\u003c\/strong\u003e GWASs identify variants associated with CAD and early-onset myocardial infarction. Bioinformatics tools impute unmeasured variants to maximize coverage, and statistical analysis identifies variants meeting the genome-wide significance threshold (p \u0026lt; 10⁻⁸).\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eModeling:\u003c\/strong\u003e A polygenic risk score is built by summing an individual's risk alleles, weighted by their effect sizes. PRS values follow a \u003cstrong\u003eGaussian (bell-curve) distribution\u003c\/strong\u003e—most people carry an intermediate number of risk alleles, while a small portion carry very few or very many.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eApplication:\u003c\/strong\u003e Genetic information is the only risk-prediction tool that is available at birth. It can be used throughout life to stratify risk and tailor prevention.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003eCritically, the PRS strategy shifts over a person's lifetime. In young and middle-aged adults, genetics can predict risk before traditional risk factors or imaging abnormalities appear. During life, the influence of lifestyle factors and their management grows. In older adults, imaging to detect atherosclerosis and its complications becomes the main diagnostic tool. But genetic information could be valuable at all stages—to predict risk in the young, to evaluate the beneficial effects of lifestyle and pharmacological interventions, and even to predict how well a patient will respond to a specific treatment such as statins or PCSK9 inhibitors.\u003c\/p\u003e\n\n\u003ch2 id=\"clinical-implications\"\u003eWhat This Means for Patients\u003c\/h2\u003e\n\u003cp\u003eSo what does all this mean for you or a family member concerned about heart disease?\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eFirst, a family history of early heart attacks matters.\u003c\/strong\u003e The twin studies and family studies confirm that genetics substantially influence CAD risk, and this risk is strongest when relatives had heart disease at a young age.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eSecond, many of the new drugs for cholesterol and triglycerides were born directly from genetic discoveries.\u003c\/strong\u003e PCSK9 inhibitors, ezetimibe, and the emerging therapies targeting ANGPTL3, APOC3, and lipoprotein(a) all trace their origins to GWAS findings. These represent a triumph of \"genetics-to-medicine\" translation.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eThird, genetic risk is not destiny.\u003c\/strong\u003e The review emphasizes that CAD results from the interplay of hundreds of variants, each with small effects, combined with environmental and lifestyle factors. Even people with high polygenic risk can potentially reduce their risk through lifestyle changes and, where appropriate, medication.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eFourth, polygenic risk scores could soon enter clinical practice.\u003c\/strong\u003e But there's a catch—the accuracy of these scores varies by ancestry. Most GWAS data come from European populations, so scores may be less predictive for people of other ancestries. Ongoing studies in Han Chinese, Japanese, and other populations (including the discovery of 43 novel loci in Japanese patients) are working to fix this gap.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eStudy Limitations\u003c\/h2\u003e\n\u003cp\u003eThe authors are careful to note several limitations of the research they reviewed:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eThe \"closest gene\" problem:\u003c\/strong\u003e Many GWAS findings may point to the wrong gene, as the 6p24\/PHACTR1\/EDN1 example demonstrates. The true causal gene can be far away or even a noncoding RNA.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAnimal model caveats:\u003c\/strong\u003e Mouse knockout experiments can produce results that contradict human genetic associations, as seen with GUCY1A1. Differences between species limit the conclusions that can be drawn.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSmall individual effect sizes:\u003c\/strong\u003e Each common genetic variant contributes only a small amount to overall risk. Even together, genetic variants capture only part of heritability.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAncestry bias:\u003c\/strong\u003e Most GWASs have focused on European-ancestry populations. Risk scores and effect estimates may not transfer perfectly to other ethnic groups.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eUnresolved mechanisms:\u003c\/strong\u003e For many loci, including the famous 9p21, the exact biological mechanism remains incompletely understood.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations for Patients\u003c\/h2\u003e\n\u003cp\u003eBased on this research, here are actionable steps patients can consider:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eKnow your family history.\u003c\/strong\u003e If you have a first-degree relative (parent, sibling, child) who had a heart attack or was diagnosed with CAD at a young age (before 55 in men, before 65 in women), discuss this with your doctor.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDon't ignore traditional risk factors.\u003c\/strong\u003e Hypertension, diabetes, smoking, and high cholesterol remain critically important—they interact with your genetic background to determine overall risk.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eTalk to your doctor about newer lipid treatments.\u003c\/strong\u003e If statins alone aren't controlling your cholesterol, medications like ezetimibe or PCSK9 inhibitors—both developed from genetic insights—may be appropriate.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about lipoprotein(a) testing.\u003c\/strong\u003e The LPA locus has among the strongest effects on CAD risk, and new targeted therapies are in clinical trials. Knowing your Lp(a) level can inform your risk profile.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eStay tuned for polygenic risk scores.\u003c\/strong\u003e As these tools become clinically validated across diverse populations, they may help guide earlier or more intensive prevention strategies, especially in younger people.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRemember that genes aren't destiny.\u003c\/strong\u003e A high genetic risk can be offset by healthy lifestyle choices. The very same genes that raise risk are also revealing the pathways—like lipid metabolism and vascular inflammation—that we can modify with diet, exercise, and medication.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat does it mean if heart disease runs in my family?\u003c\/h3\u003e\n\u003cp\u003eA family history of early heart disease raises your risk, especially if a parent or sibling had a heart attack or coronary artery disease before age 55 in men or 65 in women. Genetic factors are powerful, but they interact with lifestyle and traditional risk factors like high blood pressure, smoking, and diabetes.\u003c\/p\u003e\n\u003ch3\u003eCan I get a genetic test for heart disease risk?\u003c\/h3\u003e\n\u003cp\u003eGenetic testing for coronary artery disease is still developing. Researchers have identified over 200 genetic regions linked to heart disease risk, but each variant has a small effect. Currently, the most practical tool may be a polygenic risk score, which combines many variants. Talk to your doctor about whether testing is appropriate for you.\u003c\/p\u003e\n\u003ch3\u003eWhat is a polygenic risk score?\u003c\/h3\u003e\n\u003cp\u003eA polygenic risk score sums your risk-related genetic variants, weighted by their effect size. Most people carry an intermediate number of risk alleles. The score can predict risk from birth, before traditional risk factors or imaging show problems. However, accuracy may vary by ancestry, as most research has involved European populations.\u003c\/p\u003e\n\u003ch3\u003eAre there new treatments for high cholesterol based on genetics?\u003c\/h3\u003e\n\u003cp\u003eYes. Genetic discoveries led to medications like PCSK9 inhibitors, ezetimibe, and newer therapies targeting ANGPTL3, APOC3, and lipoprotein(a). For example, evinacumab, an anti-ANGPTL3 antibody, reduced LDL cholesterol by 47% in patients with familial hypercholesterolemia. Statins remain a mainstay, and other drugs may be added if needed.\u003c\/p\u003e\n\u003ch3\u003eDoes having heart disease genes mean I will definitely get heart disease?\u003c\/h3\u003e\n\u003cp\u003eNo. Genetic risk is not destiny. Coronary artery disease results from the interplay of hundreds of genetic variants, each with small effects, combined with lifestyle and environmental factors. Even people with high genetic risk can potentially reduce risk through healthy habits and, when appropriate, medication. The same genes reveal pathways that can be modified.\u003c\/p\u003e\n\u003ch3\u003eHow accurate is genetic risk prediction for people of different ancestries?\u003c\/h3\u003e\n\u003cp\u003eMost genetic studies have focused on European populations, so polygenic risk scores may be less accurate for other ancestries. However, large studies in Han Chinese and Japanese populations, including one that found 43 novel genetic loci in Japanese individuals, are working to improve trans-ancestry accuracy. This diversity matters because effect sizes can vary across genetic backgrounds.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eOriginal article title:\u003c\/strong\u003e kessler-schunkert-2021-coronary-artery-disease-genetics-enlightened-by-genome-wide-association-studies\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Thorsten Kessler, MD, and Heribert Schunkert, MD, from the German Heart Centre Munich, Department of Cardiology, Technical University of Munich, and the German Centre for Cardiovascular Research (DZHK e.V.), partner site Munich Heart Alliance, Munich, Germany.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePublication:\u003c\/strong\u003e \u003cem\u003eJACC: Basic to Translational Science\u003c\/em\u003e, Volume 6, No. 7, 2021, pages 610–623. Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open-access article under the CC BY-NC-ND license.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eManuscript dates:\u003c\/strong\u003e Received November 16, 2020; revised March 4, 2021; accepted April 1, 2021.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOI:\u003c\/strong\u003e 10.1016\/j.jacbts.2021.04.001\u003c\/p\u003e\n\u003cp\u003eThis patient-friendly article is based on peer-reviewed research. It is intended for educational purposes and does not replace professional medical advice. Always consult your healthcare provider about your individual heart disease risk and treatment options.\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47422993891484,"sku":null,"price":0.0,"currency_code":"EUR","in_stock":true}],"url":"https:\/\/diagnosticdetectives.com.br\/products\/your-genes-and-heart-disease-how-modern-genetics-is-revolutionizing-coronary-artery-disease-care","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}